Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03572634
Title Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Dubermatinib

Dubermatinib + Ibrutinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.